Review

Mesenchymal tumours of the gastrointestinal tract

Marta Sbaraglia1,2, Gianluca Businello2, Elena Bellan2, Matteo Fassan1,2, Angelo Paolo Dei Tos1,2

1 Department of Pathology, Azienda Ospedale Università Padova, Padua, Italy; 2 Department of Medicine, University of Padua School of Medicine, Padua, Italy

Summary

Mesenchymal tumours represent a heterogenous group of neoplasms encopassing benign, intermediate malignancy, and malignant entities. Sarcomas account for approximately 1% of human malignancies. In consideration of their rarity as well as of intrinsic complexity, diagnostic accuracy represents a major challenge. Traditionally, mesenchymal tumours are regarded as lesions the occurrence of which is mostly limited to somatic soft tissues. However, the occurrence of soft tissue tumours at visceral sites represent a well recognized event, and the GI-tract ranks among the most frequently involved visceral location. There exist entities such as gastrointestinal stromal tumours (GIST) and malignant gastrointestinal neuroectodermal tumors that exhibit exquisite tropism for the GI-tract. This review will focus also on other relevant clinico-pathologic entities in which occurrence at visceral location is not at all negligible.

Key words: mesenchymal tumours, sarcoma, gastrointestinal tract, GIST, rare tumours

Introduction

Mesenchymal tumours represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterised by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely, mesenchymal lesions may occur in the gastrointestinal (GI) tract. Some of these entities occur almost exclusively in the GI tract whereas other subtypes, when located in the GI tract, may assume distinct morphological features. The majority of sarcomas of the GI tract are represented by gastrointestinal stromal tumours (GISTs), which are the most common mesenchymal tumours in the stomach as well as in the small bowel. Benign soft tissue neoplasms show an incidence 100-fold higher than malignant ones. This group includes very common entities such as visceral lipomas, leiomyomas and haemangiomas, but also extremely rare entities such as glomus tumour and plexiform fibromyxoma. Importantly, both rarity and heterogeneity contribute to limit diagnostic accuracy. The aim of this review is to describe the clinical and pathologic features of the most common mesenchymal tumours occurring in the GI tract, focusing on the application of immunohistochemistry and, when indicated, of molecular genetics to improve diagnostic accuracy and consequently promote the most appropriate therapeutic approach.
Gastrointestinal Stromal Tumours (GIST)

GIST represents a distinctive mesenchymal neoplasm sharing immunomorphologic features with the interstitial cell of Cajal. It exhibits an exclusive tropism for the GI tract. In general GIST shows no sex predilection with a peak incidence between the 5th and 6th decades, although it may occur at any age. The estimated annual incidence ranges from 11 to 15 cases per million people, and approximately 80% of cases harbour activating mutation of KIT and PDGFRA. Paediatric GISTs represent a clinically as well as a molecularly distinct group, most often featuring succinate dehydrogenase (SDH) genetic aberrations. Interestingly, as demonstrated by both surgical and autopsic series, submillimetric gastric GISTs (so-called microGISTs) are found in approximately 20% of the general population. Notably, the vast majority of these lesions do not progress into clinically meaningful lesions, but undergo instead regressive changes and calcification. Notably, owing to its molecular characteristics GIST represents a still unsurpassed model of molecular targeted therapy of solid tumours.

The most common locations from which GIST may arise are the stomach (50-60%), followed by the small intestine (20-30%), the large bowel (5%) and the oesophagus (5%). More rarely, GISTs primitive of the peritoneum are reported, although most often they represent pedunculated masses detached from the outer visceral wall. Important prognostic factors are tumour size, mitotic activity and anatomic site, which are the basis for the prediction of risk of aggressive biologic behaviour. Moreover, the risk of abdominal dissemination is dramatically increased by intraoperative tumour rupture (up to 90%). Importantly, all the aforementioned features have been incorporated into various risk assessment schemes.

Localised disease is principally treated surgically, with the addition of imatinib as adjuvant therapy in high-risk patients. Advanced and metastatic disease currently requires a therapy with three consecutive lines of receptor tyrosine kinase (RTK) inhibitors (imatinib, sunitinib, and regorafenib) all directed against the action of mutant KIT and PDGFRA. Importantly, the mutational status of these genes predicts response to RTK inhibitors and assumes prognostic value.

SDH-deficient GIST represents a clinically and pathologically distinct subgroup. It often shows propensity to arise from the stomach, to occur in children and young adults and, outside the context of Carney-Stratakis syndrome, exhibits marked female predominance. Compared to the classic form of GIST, it shows a higher risk of loco-regional lymph nodes spreading, even though the clinical behaviour remains distinctively indolent. On the other hand, NF-1 associated GISTs are typically multicentric, most often arise from the small bowel, and also have a rather indolent course. Grossly, localised GIST presents as a well circumscribed mass of variable size with the cut surface frequently showing foci of haemorrhage. On the other hand, advanced disease often presents as a larger lesion associated with multiple smaller peritoneal nodules.

On histology, based on morphology, GISTs can be categorised into three general groups: spindle cell (70%), epithelioid (20%), and mixed spindle and epithelioid cell type (10%). Spindle cell GIST is composed of uniformly eosinophilic spindle cells with indistinct cell borders organized in short intersecting fascicles. The neoplastic cells have light eosinophilic cytoplasm, often with indistinct cell borders. Nuclei tend to be oval and uniform in appearance, often with vesicular chromatin. A peculiar feature, most often observed in gastric neoplasms, is represented by the presence of striking juxtanuclear cytoplasmic vacuoles. The presence of nuclear palisading is seen in a minority of cases and, as it is frequently observed in both smooth muscle and neural tumours, may represent a potentially misleading feature. Microcystic stromal degeneration, fibrosis as well as stromal haemorrhage may represent a prominent finding in some cases.

Epithelioid GIST is composed of cells exhibiting abundant eosinophilic or clear cytoplasm. Nuclei tend to be round-to-ovoid and uniform. In comparison with spindle cell GIST, tumour cells tend to exhibit a nested pattern of growth. Some cases may exhibit a...
striking “plasmacytoid” appearance. Epithelioid GIST arises most often in the stomach and are frequently associated with PDGFRA gene mutations. Mixed cell type GIST may feature abrupt transition between spindle cell and epithelioid areas or as an alternative the two cell types may be intermingled. In approximately 10-20% of cases (almost exclusively in the small bowel), hyaline or fibrillary brightly eosinophilic structures known as “skeinoid fibres” can be seen. These structures appear to be composed of nodular tangles of collagen and, typically, exhibit PAS positivity. GIST arising in the small bowel also relatively often may feature a nesting, paraganglioma-like growth pattern. Prominent myxoid change can be seen rarely. Nuclear pleomorphism is not a typical feature of GIST, although it can be observed in approximately 2% of cases. Abrupt morphologic progression to high-grade pleomorphic sarcoma can also be rarely observed (so called dedifferentiated GIST). SDH-deficient GIST not only represents a clinically distinctive entity, but also shows relatively peculiar morphologic features. A distinctive multinodular pattern of growth is often seen associated with a predominantly epithelioid morphology (Fig. 3). Even if there are cases in which mitotic activity is remarkably high, in most GIST it tends to be low. In fact, mitotic count (which represents a major prognostic determinant) is assessed on 5 mm². The use of mm² instead of High-Power Fields (HPF) has the advantage of overcoming inconsistencies due to the use of microscope with variable aperture of the oculars. Not infrequently pathologists are confronted with biopsies originating from post-treatment GIST. Depending on the level of response to RTKs inhibitors variable amounts of viable cells can be seen and relatively often most of the tissue can be merely represented by diffusely hyalinised fibrotic tissue. In consideration of the current clinical as well as therapeutic implications immunophenotypic analysis has gained a major diagnostic role. Most cases are KIT (CD117) immunoreactive (Fig. 4A), even if has to be recognized that there are lesions with typical cytoarchitectural features of GIST lacking KIT expression. This phenomenon occurs in 5-7% of cases overall and in up to 18% of gastric GIST. A significant proportion of KIT-negative cases contains mutations of the PDGFRA gene and tends to exhibit an epithelioid morphology. In this cases expression of PDGFRA is commonly seen. The pattern of KIT expression is usually cytoplasmic and diffuse, however, up to half of cases will also show a dot-like accentuation of the staining. More rarely a dot-like pattern is seen in the absence of diffuse cytoplasmic staining. Approximately 50% of KIT negative GIST actually express DOG1 (anoctamine-1) (Fig. 4B). In addition to KIT and DOG1, GIST frequently expresses CD34 in 60-70% of cases, smooth muscle actin in 30% of cases. Desmin and cytokeratin can be seen in less than 2% of cases. SDHA and SDHB immunostaining is currently regarded as extremely helpful in recognizing SDH-deficient GIST. In fact, whatever the mutations of SDH subunits loss of SDHB expression is seen (Fig. 5). On the other hand, loss of SDHA predict the presence of mutations in the SDHA gene. Following therapy with TRK inhibitors non-canonical immunophenotypes can be observed, such as diffuse
expression of myogenic or epithelial differentiation markers. From a genetic standpoint, GIST represents a relatively heterogeneous and complex group of lesions. Gain-of-function mutations of the oncogenes located on chromosome 4 (4q12) encoding for the type III receptor tyrosine kinases KIT and PDGFRA can be found in approximately 80% of cases. With exceedingly rare exceptions they are mutually exclusive and result in the constitutive activation of either KIT or PDGFRA. Normally, KIT and PDGFRA, are activated by binding of their respective ligands, i.e., stem-cell factor (Steel factor) and platelet-derived growth factor A. Downstream oncogenic signalling for both KIT and PDGFRA involves the RAS/MAPK and the PI3K/AKT/mTOR pathways. Mutations can be deletions, insertions and missense mutations involving exon 11 of the KIT gene (encoding for the juxtamembrane domain of the KIT receptor) in approximately 70% of GIST; exon 9 of KIT (encoding for the extracellular domain of the receptor) in less than 10%; exon 13 and 17 of KIT (encoding for the intracellular ATP-binding pocket and activation loop domains, respectively) in a small subset of cases. Approximately 10% of GIST harbour PDGFRA gene mutations involving exons 12, 14 and 18, with 70% being represented by the exon 18 D842V mutation. The D842V mutation is known for making GIST primarily resistant to available RTK inhibitors. However, the recently approved avapritinib seems to be effective also on this type of mutation. Approximately 10-15% of GIST is wild type for both KIT and PDGFRA. They represent a family of tumours with distinctive molecular pathogenesis and, to some extent, different natural histories. Their classification is rapidly evolving as of today, and one may identify: 1) SDH deficient GIST; 2) NF1-related GIST; 3) others, including those with the BRAF V600E mutations. Approximately one half of wild type GIST (WT GIST) are marked by alterations involving the SDH complex, which plays a key role in the mitochondrial respiratory cell function. A group of them includes “paediatric” GIST and can be associated with the Carney triad that, when full blown, is characterised by the concomitant occurrence of GIST, pulmonary chondromas and paragangliomas. On the other hand, a group of SDH-deficient GIST carries mutations of the SDHA, SDHB or...
SDHC units of the SDH complex, and may be related to the Carney-Stratakis syndrome, a dominant autosomal disorder represented by association of GIST and paragangliomas. WT GIST can occur in the context of NF-1, wherein the mutation of the NF1 gene leads to loss of neurofibromin, and consequent activation of the RAS pathway. Finally, the remaining SDHB-positive WT GIST are probably a basket of different conditions: some were reported to have the V600E mutation of BRAF or, more rarely, of HRAS, NRAS, PI3K. Recent experience would indicate that a significant proportion of so-called “quadruple negative” GIST exhibits NF1 gene mutations that may be somatic or more frequently germline. As this happens in absence of clinical evidence of Type 1 neurofibromatosis, they possibly represent examples of subclinical forms of the syndrome. Using a Massive Parallel Sequencing approach an ETV6-NTRK3 gene fusion has been recently detected in a quadruple-negative GIST. As WT GIST tend to be not responsive to tyrosine kinase inhibitors (but keeping in mind that this alteration is very rare) molecular therapy targeting NTRK has been successfully applied.

**Neoplasm with fibroblastic/myofibroblastic differentiation**

**Desmoid fibromatosis**

Desmoid fibromatosis represents a locally aggressive, non-metastasising myofibroblastic neoplasm that may occur at extra-abdominal (60%), abdominal (25%) and intra-abdominal anatomic sites (15%)\(^3\). Intra-abdominal lesions are usually located in the pelvis or in the mesentery. Mesenteric desmoids can be sporadic or be associated with a variant of familial adenomatous polyposis syndrome (Gardner’s syndrome). This syndrome is defined by the presence of synchronous of metachronous multiple adenomatous polyps, osteomas, epidermic cysts, and desmoid fibromatosis. Intra-abdominal desmoid fibromatosis occur predominantly in young adults. Macroscopically, tumours appear as a solitary mass with diameter ranging from 5 cm to 10 cm. The cut surface is whitish and hard. Desmoid fibromatosis typically shows poor circumscription often with infiltration of the surrounding soft tissues. Microscopically, the tumour is composed of a monotonous spindle cell proliferation arranged in long sweeping fascicles set in a collagenous background (Fig. 6). A useful diagnostic clue is represented by the fact that neoplastic cells often exhibit a relatively regular distribution without nuclear overlapping. Both cellularity and amount of collagenous stroma can be variable. Nuclear atypia is generally absent and mitotic figures may vary in number but are usually not numerous. Myxoid change of the stroma may occasionally occur. Desmoid fibromatosis exhibits nuclear immunopositivity for beta-catenin (Fig. 7) and multifocal positivity for smooth muscle actin. Nuclear expression of beta-catenin protein represents the consequence of mutations of the CTNNB1 gene that occurs in approximately 85% of sporadic cases. In Gardner syndrome-associated cases the same phenomenon is determined by the mutation of...
the APC gene. A sharp debate surrounds the potential prognostic meaning of CTNNB1 gene mutations (it has been suggested that the 45F mutation associates with higher rates of local recurrences) that is still unsettled. In the past, the therapeutic approach to desmoid fibromatosis has been mostly represented by surgical excision. The use of radiotherapy as well as of systemic treatments (which include hormone antagonists, tyrosine-kynase inhibitors, low dose cytotoxic chemotherapy) has been suggested for progressive lesion. More recently, in consideration that in a significant subset of patients repeated surgery may lead to increased recurrence rates, whereas spontaneous regression is by contrast observed, a “wait and see” approach has been suggested unless clear clinical progression is observed.

**INFLAMMATORY MYOFIBROBLASTIC TUMOUR**

Inflammatory Myofibroblastic Tumour (IMT) is a rare, locally aggressive and rarely metastasizing mesenchymal tumour of young adults, composed of myofibroblasts and fibroblasts set in an inflammatory background that includes plasma cells, lymphocytes and/or eosinophils in variable amounts. IMT is most often observed in the lungs although it may occur anywhere in the body, including the abdominal soft tissue, mesentery, omentum, and the GI tract (Fig. 8).

Three main morphologic patterns are recognised. The “myxoid pattern” is characterized by loosely arranged plump or spindled myofibroblasts embedded in an oedematous myxoid background rich in plasma cells, lymphocytes and eosinophils to the extent that it can mimic granulation tissue (Fig. 9). The “hypocellular pattern” consists of a compact proliferation of spindle cells associated with variable myxoid/collagenous stroma and a rich inflammatory infiltrate. Finally, the “hypocellular fibrous pattern” is characterised by low cellularity, collagenous stroma and sparse inflammatory cells. One or more of these patterns may be identified in a single IMT. Dystrophic calcifications and osseous metaplasia represent rare findings in IMT. Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a clinically aggressive form of IMT, characterized by epithelioid tumour cells featuring vesicular nuclei and prominent nucleoli, set in a myxoid stroma; neutrophils are often present. It occurs predominantly intra-abdominally. Immunohistochemically, IMT may show variable positivity for SMA, calponin and desmin. Cytokeratins are focally positive in about 30% of cases. More than 50% of IMTs present ALK positivity, which is related to ALK gene rearrangement. Interestingly, ALK immunohistochemical pattern varies according to ALK fusion partner: RNBP2-ALK generates a nuclear membrane pattern, RRBP1-ALK a perinuclear accentuated pattern, and CLTC-ALK a granular cytoplasmic one. The diffuse cytoplasmic pattern is the most frequent and is associated to many other ALK fusion variants. A subset of IMT present ROS1 gene rearrangements and are usually associated with immunohistochemical cytoplasmatic expression of ROS1. The APC gene. A sharp debate surrounds the potential prognostic meaning of CTNNB1 gene mutations (it has been suggested that the 45F mutation associates with higher rates of local recurrences) that is still unsettled. In the past, the therapeutic approach to desmoid fibromatosis has been mostly represented by surgical excision. The use of radiotherapy as well as of systemic treatments (which include hormone antagonists, tyrosine-kynase inhibitors, low dose cytotoxic chemotherapy) has been suggested for progressive lesion. More recently, in consideration that in a significant subset of patients repeated surgery may lead to increased recurrence rates, whereas spontaneous regression is by contrast observed, a “wait and see” approach has been suggested unless clear clinical progression is observed.

**Figure 8.** Inflammatory Myofibroblastic Tumour may rarely occur in gastrointestinal tract. In this case neoplastic cells involve the *muscolaris mucosae* of the small bowel.

**Figure 9.** Inflammatory Myofibroblastic Tumour. This tumour is composed of spindle cells, set in a fibrous stroma associated with a prominent inflammatory infiltrate, rich in plasma cells, lymphocytes and eosinophils.
of IMT may feature the rearrangement of the \textit{NTRK3} gene \textsuperscript{31}. As is the case of ALK and ROS1, \textit{NTRK3} represents a druggable biomarker. Approximately 25\% of extrapulmonary IMT may recur, but metastases are rare (less than 5\%). ALK-negative IMTs seem to be related to a higher frequency of metastasis. However, reliable prognostic indicators for IMT have not been validated yet. As mentioned above, epithelioid IMT have a more aggressive clinical behaviour \textsuperscript{32}.

**Solitary Fibrous Tumour**

Solitary fibrous tumour (SFT) is a rare neoplasm that even if originally reported as pleural-based tumour, can actually occur at any anatomic site. Approximately 80\% of cases are deep-seated \textsuperscript{33,34}. SFTs have been described in different parts of the GI tract, liver and pancreas included \textsuperscript{35-38}. Microscopically, SFT are composed by a patternless proliferation of spindle cells embedded in a collagenous background featuring distinctive branching, thin-walled blood vessels organized in a “staghorn” configuration (so called haemangiopericytoma–like vascularization) (Fig. 11) \textsuperscript{38}. Cellular variation is typically observed in classic examples. Three additional SFT subtypes are recognised: fat-forming SFT is characterised by the presence of mature adipose tissue \textsuperscript{39};
MESENCHYMAL TUMOURS OF THE GASTROINTESTINAL TRACT

Giant cell-rich SFT features multinucleated giant cells often lining angiectoid spaces; dedifferentiated SFT show transition from classic SFT to a high-grade sarcoma. Immunohistochemically, SFT is strongly positive for CD34, bcl-2 and CD99 (70% of cases). STAT6 is the most specific and sensitive marker (Fig. 12), being expressed in almost all SFTs. STAT6 expression is related to a specific recurrent gene fusion involving STAT6 and NAB2 genes.

Approximately 12-22% of cases of SFT are malignant. Malignancy-associated features are high cellularity, nuclear pleomorphism, necrosis and more than 4 mitoses per 10 HPF. The metastatic risk can be assessed on the basis of mitotic count (2 or more mitoses per mm²), patient age (55 years or more) and tumour size. However, the absence of these criteria does not exclude a possible aggressive behaviour and no SFT should be regarded as benign.

SFT may enter in differential diagnosis with GISTs, schwannomas, benign smooth muscle tumours and monophasic SS. Immunohistochemical analysis for STAT6 is usually sufficient to assess the correct diagnosis.

INFLAMMATORY FIBROID POLYP

Inflammatory fibroid polyp is a benign neoplasm featuring a polyoid configuration, composed of a hypocellular fibroblastic proliferation associated with a variably prominent inflammatory infiltrate, rich in eosinophils. It most often arises in the stomach followed by the ileum but may involve the whole digestive tract. The tumour is typically located in the submucosa or restricted to the mucosa that can be ulcerated. Middle-aged adults are typically affected, with a slight female predominance.

Small lesions are asymptomatic and most often discovered incidentally. Large masses are associated with abdominal pain and bleeding due to mucosal ulceration. Intussusception is a common presentation for small intestine tumours.

Tumours can appear sessile or polyloid, and range in size from few millimetres to large masses. Histologically, inflammatory fibroid polyp is a hypocellular lesion composed short spindled and stellate cells showing fine chromatin, small or indistinct nucleoli, and scant eosinophilic cytoplasm (Fig. 13). The stroma may be myxoid or collagenous, with a prominent mixed inflammatory infiltrate, often rich in eosinophils. Concentric fibrosis (onion-skin) distributed around blood vessels represents a distinctive finding.

Immunohistochemically, neoplastic cells express CD34 and rarely smooth muscle actin. KIT, DOG1, desmin, S100, SOX10, and keratins are all negative. The differential diagnosis includes IMT, leiomyoma, and plexiform fibromyxoma.

Most cases, particularly when located in the small bowel, harbour PDGFRA gene mutation. Exon 18 mutations, usually c.2525A>T (p.D842V) are associated with a gastric location, whereas exon 12 mutations are almost identified in small intestine tumour. Only rare cases are associated with germline PDGFRA gene mutations. Inflammatory fibroid polyp is a benign tumour. Local recurrences and distant metastasis have not been reported.

PLEXIFORM FIBROMYXOMA

Plexiform fibromyxoma, also referred as plexiform angiomyxoid myofibroblastic tumour, is a benign mesenchymal tumour arising almost exclusively in the stomach. The tumour occurs in the antrum and pyloric region of the stomach, but duodenum may be very rarely involved. Age range is rather broad, and include childhood with equal distribution in male and females. Clinically, gastrointestinal bleeding due to mucosal ulceration, weight loss and pyloric obstruction may be observed.

Macroscopically, the tumour appears like as gelatinous or haemorrhagic multinodular mass, ranging in size from few centimetres to large masses. The tumour is typically located in the muscularis propria and protruding into the serosa. Histologically, the neoplasm features a distinctive plexiform pattern of growth. The nodules are composed of bland oval to spindled cells with indistinct cytoplasm, set in a myxoid, fibromyxoid or collagenous matrix associated with a rich thin-walled capillary network (Fig. 14).
creased cellularity is observed in those rare tumours occurring in the duodenum. Nuclear atypia is usually absent and mitotic activity is generally low. Neoplastic cells express SMA and occasionally are immunopositive for desmin and h-caldesmon whereas KIT, DOG1, ALK and S100 are consistently negative. Differential diagnosis includes SDH-deficient GIST, plexiform schwannoma and inflammatory myofibroblastic tumour. KIT and PDGFRα mutation have not been reported. Molecularly, MALAT1-GLI1 fusions and GLI1 polysomy have been identified in a subset of tumours resulting in GLI1 overexpression. Plexiform fibromyxomas are benign lesions with no reports of recurrence or metastasis however in some cases massive gastric bleeding has proved fatal.

Neoplasm with adipocytic differentiation

LIPOMA

Lipomas are the most common benign soft tissue tumours, most often arising in the soft tissues of the extremities and trunk. Lipomas more rarely may also occur in the submucosa or subserosa along the whole gastrointestinal tract; the cecum and the ascending colon being the most common sites followed by the ileum, stomach and oesophagus. Rarely, gastrointestinal lipomas may be intramucosal, such cases may rarely be associated with Cowden syndrome. The reported incidence of large bowel lipomas is between 0.2% to 4.4% of endoscopies, with possible slight female predilection and a peak incidence in the 6th decade. Signs and symptoms of GI lipomas are linked to size (highly variable from 2 to > 10 cm) and location. Most patients are asymptomatic, although abdominal pain, and intestinal obstruction have been reported. The histological appearance of lipomas consists in a proliferation of mature adipose tissue, with no cytologic atypia. Larger lesions may be accompanied by overlying mucosal ulceration. Lipoma subtypes, such as angiolipomas have also been described to occur in the GI tract. Molecularly, benign lipomas harbour simple genetic alteration in about 75% of cases, among which the most common is HMGA2 gene rearrangements. Surgical and endoscopic excision are the treatment of choice for large or symptomatic gastrointestinal lipomas.

WELL DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA

Liposarcomas are the most common mesenchymal malignancy and are currently classified according to the WHO 2020 as atypical lipomatous tumour (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS) and pleomorphic myxoid liposarcoma. While the primary site of occurrence is usually the soft tissue of the limbs, trunk or retroperitoneum, primary gastrointestinal lipo-
sarcomas are much rarer with incidence at autopsy reported to be between 0.1% and 5.8%. Primary gastrointestinal liposarcomas show slight male predominance and tend to occur in middle-aged individuals. Liposarcomas also display a higher tropism for the submucosal layer and muscularis propria of the oesophagus, closely followed by the stomach, small and large intestine. When arising in visceral sites, they usually present as already voluminous polypoid masses with slow growth. Patients usually present with symptoms related to anatomic location, which include dysphagia, cough, vomit, foreign body sensation and weight loss.

Albeit being the most common subtype of liposarcoma, in GI tract WDLPS seems to show a lower incidence than its dedifferentiated counterpart. Both are genetically driven by amplification of \( MDM2 \) and \( CDK4 \) genes that lead to the overexpression of the proteins thereof.

Grossly the appearance of WDLPS strongly depends on the proportion of lipomatous and fibrous components and varies from a uniformly yellow mass, similar to a lipoma, to a white-greyish lobulated mass on cut surface.

On histology, WDLPS is composed of a mature lipomatous proliferation intersected by thick fibrous septa, with variation in cell size and at least focal nuclear atypia in adipocytic and/or stromal cells (Fig. 16). Mitotic figures are rare. Lipoblasts may be present in variable amounts (from many to none) (Fig. 17); however, this feature is not required for the diagnosis of WDLPS. Rarely, foci of heterologous metaplasia may be observed. As mentioned MDM2 overexpression is consistently observed (Fig. 18).

Dedifferentiated liposarcomas (DDLPS) is characterised by a broad morphological spectrum. It is defined by the the presence of abrupt transition from well differentiated liposarcoma to high grade non-lipogenic sarcoma (Fig. 19). Most often the dedifferentiated component is pleomorphic however it can be also composed by a monomorphous spindle cell proliferation. Areas of heterologous differentiation (most often...
myogenic) may also be found. Multivisceral surgical resection is the mainstay of treatment. Although DDPLS and WDLPS are the most common subtypes of liposarcomas described in the GI tract, a few case reports also described the exceptional occurrence of myxoid liposarcomas (MLPS). Myxoid liposarcoma is composed of cytologically bland spindle to ovoid cells associated with monovacuolated lipoblasts, set in a myxoid stroma with prominent plexiform capillary network. Myxoid liposarcoma is MDM2 negative and characterized genetically by a DDIT3 gene rearrangement that represent a useful diagnostic confirmatory finding.

**Epithelioid Pleomorphic Liposarcoma**

Epithelioid pleomorphic liposarcoma (EPL) represents a subset of pleomorphic liposarcomas in which an epithelioid morphology predominates. Diagnosis is based on the detection of pleomorphic lipoblasts that unfortunately may be minimally represented. A significant proportion of cases occur in the GI tract of adults. Clinically EPL is a high-grade sarcoma with a dismal prognosis.

**Smooth Muscle Neoplasms**

**Leiomyoma**

Leiomyoma is a rare benign mesenchymal tumour showing smooth muscle differentiation and represents approximately one third all mesenchymal neoplasms of the GI tract. Leiomyomas predominantly occur in the oesophagus, colon, and rectum and rarely arise in the stomach and small intestine. Incidental small nodules, less than 7 mm, are recognised in oesophagogastric resections done for other reason. Most cases are sporadic, but exceedingly rare cases occur in association with Alport syndrome. Histologically, the tumour is composed of fascicles of spindled cells with blunt-ended nuclei set in eosinophilic fibrillary cytoplasm. Myxoid liposarcoma is MDM2 negative and characterized genetically by a DDIT3 gene rearrangement that represent a useful diagnostic confirmatory finding.
GIST, which may show similar morphological features. However, KIT (CD117) is consistently negative in leiomyomas. Focal expression of DOG1 can be observed in smooth muscle tumours, therefore representing a potential diagnostic pitfall, as is the presence in leiomyomas of hyperplasia of the interstitial cells of Cajal (KIT positive) (Fig. 22). Leiomyomas of GI tract are benign tumours, with no risk of recurrence or distant spread.

**Leiomyosarcoma (LMS)**

Leiomyosarcoma is an extremely rare malignant neoplasm showing smooth muscle differentiation. In the GI tract it most commonly occurs in the small intestine (40%) and colorectum (40%) and more rarely in the stomach (10%) and oesophagus (10%) 70,71. In the anorectum and in the oesophagus LMS is relatively more common than GIST. Leiomyosarcoma occurs typically in adult patients (peak incidence is in the sixth decade) with the exception of gastric LMS which tends to arise in younger patients (median age: 37 years) 71. Interestingly visceral LMS, particularly those arising in children, may be related to immunosuppression and aetologically linked to Epstein-Barr Virus infection 72. In oesophageal and gastric cases, a slight male prevalence has been described. Leiomyosarcomas may present as polypoid or lobulated intraluminal tumours or as a large solid and necrotic mass 71,73-75.

Microscopically, LMS is composed of long intersecting fascicles of spindle cells featuring abundant eosinophilic cytoplasm and blunt ended nuclei (Fig. 23). Moderate to severe nuclear atypia and in some cases overt pleomorphism are observed. Mitoses tend to be numerous, although rare tumours with low mitotic counts have been reported 71,73. Necrosis may be present. Immunohistochemically the vast majority express smooth muscle actin, whereas 70-80% of LMS stain with desmin and/or H-caldesmon 70. Importantly about 30% of LMS may exhibit multifocal positivity for cytokeratin and CD34 74,76. The main differential diagnosis is with GIST, the clinicopathologic features of which have already been described.

EBV-associated smooth muscle tumours can show a range of histological appearances, from lesions mimicking leiomyomas to lesions composed entirely of small round to ovoid blue cells. These are positive for SMA, with variable desmin positivity. All show diffuse, strong staining for EBV-encoded small RNA (EBER), which is not seen in conventional leiomyosarcoma. EBV-related LMS should be considered in immunosuppressed patients or in patients with multiple synchronous or metachronous tumours 77. Schwannoma may also enter the differential diagnosis. In the GI tract, schwannomas tend to be cellular, with peripheral lymphoplasmacytic aggregates, and by immunohistochemistry they are diffusely positive for S100, and negative for SMA and desmin.

Leiomyosarcomas are aggressive neoplasms, with up to 80% local recurrence rate and 55-70% metastatic rate. Tumour size > 5 cm appears to be a negative prognostic factor. Interestingly, in the GI-tract, mitotic counts and nuclear atypia seem not to correlate with outcome 70,71,73. Different classes of leiomyosarcomas, based on gene expression, have been proposed associated with different outcomes; however, these data are not currently used for clinical decision making 78,79.
Tumours with neural differentiation

**Mucosal Schwann Cell Hamartoma**

Mucosal hamartoma is a benign neural lesion of the GI tract characterised by an intramucosal Schwann cell proliferation. This peculiar lesion of GI typically occur in adults with a median age at diagnosis of 60 years. A slight female predominance has been observed. Most mucosal hamartomas arise in the left colon, and are discovered incidentally at screening colonoscopy. The lesions endoscopically appear as subcentimetre polyps. Histologically mucosal hamartoma is composed of intramucosal proliferation of uniform spindle cell with tapering or wavy nuclei (Fig. 24). Mitotic figures and nuclear atypia are absent. The cells immunohistochemically express diffusely S100 protein (Fig. 25). Mucosal hamartoma is entirely benign and is not associated with syndromes such as NF1 or NF2.

**Schwannoma**

Schwannoma is a benign spindle cells neoplasm showing schwannian differentiation, accounting for approximately 3% of all GI mesenchymal tumours, the incidence of GIST being 50 times higher. It can occur anywhere in the GI tract, but it predominates in the stomach with only rare occurrences in the lower oesophagus, colon, and rectum. Schwannoma arises in elderly patients with a female predilection. The tumour is located in submucosa or muscularis propria bulging into the lumen, sometimes ulcerating the mucosa. It appears as solid mass or polypoid lesions typically lacking intratumoural haemorrhage and necrosis. Small size tumours are discovered incidentally during endoscopic procedures, whereas large masses may cause gastrointestinal bleeding due to mucosal ulceration, or mass-like symptoms. Microscopically, gastrointestinal schwannomas are well-circumscribed, with a distinctive peripheral lymphoid cuff often containing germinal centres (Fig. 26). Thick-walled or hyalinised blood vessels are less fre-
MESENCHYMAL TUMOURS OF THE GASTROINTESTINAL TRACT

quent in GI schwannoma (Fig. 27) that also lacks the typical combination of Antoni A and Antoni B areas generally observed in schwannomas of soft parts. The tumour is uniformly cellular and is composed of spindle cell, with tapering nuclei and palely eosinophilic cytoplasm, organised in a fascicular or whorled pattern of growth. Scattered cells with nuclear enlargement and degenerative pleomorphism are common. A low mitotic count is observed, and necrosis is typically absent. The tumour stroma is variable from collagenous to myxoid sometimes contain foci of foamy histiocytes. A subtype of schwannoma relatively often observed in the GI tract is the microcystic/reticular subtype. It appears as an unencapsulated submucosal lesion in the stomach, small bowel, and colon. Microscopically it is characterised by a distinctive reticular pattern of growth associated with formation of microcystic structures. Neoplastic cells are strongly and diffusely positive for S100 (Fig. 28) and in most cases for GFAP and nestin. Most of conventional schwannoma either sporadic or associated with NF2 syndrome are associated with loss of heterozygosity at NF2 but most cases of GI schwannoma lack NF2 gene alterations, suggesting that they may represent a morphologically and genetically distinct group of peripheral nerve sheath tumours. Gastrointestinal schwannomas are benign lesions, long-term follow-up shows no recurrences or metastases.

Perivascular neoplasms

**Glomus Tumour**

Glomus tumour is a mesenchymal neoplasm composed of perivascular modified smooth muscle cells. Most often the tumour occurs in peripheral soft tissue, although viscera involvement has been reported including the GI tract. In the GI tract the region of antrum is most often involved followed by oesophageal and intestinal locations. Glomus tumour occurs predominantly in adults, although a broad age distribution is reported, with strong female predilection. Small lesions are usually asymptomatic and represent an incidental finding. In case of larger lesions, upper GI bleeding, abdominal pain, or reflux-type symptoms may occur. Glomus tumour of the GI tract is typically a single lesion, although multifocality has been described in approximately 10% of patients. Occurrence of multiple familial glomus tumour is due to inactivating mutations in the glomulin gene (GLMN). Most sporadic cases are associated with NOTCH family gene rearrangements. **BRAF** gene mutations are reported in 6% of patients. Macroscopically, the tumour appears like as a well circumscribed intramural mass, often multinodular. Extension into the mucosa and the serosa may occur. Histologically the tumour is composed of uniform round cells characterised by sharply defined cell borders, moderate amount of palely eosinophilic cytoplasm and central dark round nuclei with inconspicuous nucleoli (Fig. 29). Foci of oncocytic and epithelioid transformation may be observed. The neoplastic cells are organised in nodules, sheets and trabeculae.
Malignant gastrointestinal neuroectodermal tumour/Clear cell sarcoma of the GI tract

Malignant gastrointestinal neuroectodermal tumour (M-GNET) represents a highly aggressive mesenchymal tumour closely related to clear cell sarcoma (CCS) of soft parts but with distinctive clinical, molecular and immunomorphological features. Unlike CCS, M-GNET in fact is usually negative for melanocytic markers such as melanA and HMB45 and whereas classic CCS most often harbour EWSR1-ATF1 gene fusions, M-GNET is more frequently associated with EWSR1-CREB1 gene translocations. In consideration of these distinctive features, in the GI tract the alternative name of malignant gastrointestinal neuroectodermal tumour has been recently proposed. To date CCS and M-GNET are regarded as two distinct entities and classified separately by WHO classifications of both soft tissue and gastrointestinal tract, and are included in the group of tumours of uncertain differentiation. M-GNET occurs most frequently in the small bowel followed by stomach and large bowel but virtually can arise anywhere in GI tract including the oral cavity. The tumour affects predominantly adults, with a peak incidence at 40 years of age. There is no different distribution between male and female patients. Clinical symptoms include anemia, weight loss, pain and, when the tumour occur in small bowel, intestinal obstruction. The M-GNET is a highly aggressive tumour with an overall mortality ranging between 35% and 75%. Recurrences and metastases can occur even after many years from diagnosis. Unlike the vast majority of sarcomas in which lymph node spread is exceedingly rare, in M-GNET shows nodal metastases in approximately 50% of cases.

Macroscopically, tumours appear as a well circumscribed firm nodule located into the submucosa of the involved viscera, with a diameter that range from few centimetres to large masses. Histologically, M-GNET are composed of macronucleolated epithelioid and spindle cells, organised in large nodules demarcated by thick fibrous septa. The neoplastic cells show small amount of eosinophilic cytoplasm and only scattered neoplastic cells show clear cytoplasm (Fig. 30). Multinucleated giant cells are seen in half of the cases (Fig. 31). In M-GNET the most distinctive morphologic feature is represented by the presence of pseudopapillary and/or pseudoalveo-
lar pattern of growth. Mitotic activity is variable from scattered mitotic figures to higher mitotic index with also more than 20 mitoses/2 mm². The tumour cells are usually positive for S100 and SOX10 (Fig. 32), whereas lack the expression of melanocytic markers such as melanA and HMB45. Furthermore, the tumours are consistently negative for KIT, DOG1, pancytokeratins and for markers of smooth muscle differentiation.

The main differential diagnosis includes metastatic malignant melanoma that shares with M-GNET some morphological features such as the nested growth pattern and the diffuse immunexpression of S100 and SOX10. Of course lack of expression of melanocytic markers in M-GNET can be helpful in the differential diagnosis, even if it is important to highlight that most sarcomatoid melanomas can also loose expression of HMB45 and melan-A. In this context, the identification of molecular alteration, characteristic for M-GNET, may represent the ony way to achieve the correct diagnosis.

**Synovial sarcoma**

Synovial sarcoma is a malignant mesenchymal neoplasm representing 10% of all soft tissue tumours.
Figure 34. Synovial sarcoma, monophasic. This highly cellular neoplasm is composed of monomorphic, atypical spindle cells.

Figure 35. Synovial sarcoma, biphasic. Epithelial component exhibits a glandular configuration.

Figure 36. Synovial sarcoma. Pancytokeratins expression in monophasic SS (A); biphasic SS (B). Nuclear TLE1 expression is consistently observed but tends to exhibit low specificity (C). Currently the best marker is represented by the expression of SS18-SSX fusion-specific antibody (D).
which typically occurs in lower limbs of children and young adults 99. Synovial sarcoma of the GI tract are extremely rare: in this context, the stomach is the most common location (Fig. 33), although SS of the oesophagus, small and large bowel and liver have also been reported 99,100.

Synovial sarcoma can be morphologically subdivided in monophasic, biphasic and poorly differentiated variants 99, the monophasic one being most common in the GI tract 3. Both the monophasic and biphasic variants are characterised by a monomorphic spindle cell population arranged in fascicles (Fig. 34) set in a variably collagenous matrix, and associated with with an haemangiopericytoma-like vascular pattern 32,99. Biphasic SS in addition to the spindle cell component, presents an epithelial component, usually organised in nests, cords or featuring overt glandular (Fig. 35), architecture 32,99. Interestingly, a predominantly monophasic epithelial pattern has also been described 101. Poorly differentiated SS (PDSS) make up the 20% of SS and it is further subdivided in three groups: i) a round cells subtype with necrosis and high mitotic count, ii) a large epithelioid cell subtype, also associated with rhabdoid features, and iii) a high grade spindle cell subtype 102. Tumour size greater than 5 cm, presence of neural and vascular invasion, p53 overexpression, and high proliferation index are histological features associated with higher risk of tumour relapse 99. Immunohistochemically, SS is characterized by the expression of epithelial markers (i.e. EMA, cytokeratins) (Fig. 36A and 36B) together with CD99 and TLE1 (Fig. 36C) 99. Cytokeratin expression varies among different SS subtypes: while cytokeratins expression is recognisable in the majority of biphasic SSs, it drops to 60-70% in the monophasic subtype 99. Moreover, PDSS is characterised by cytokeratin expression only in 50% of cases 102. High molecular weight cytokeratins are more sensitive than low molecular weight cytokeratins, but the most sensitive marker of epithelial differentiation is EMA 102. S100 positivity is reported between 30-60% of SS, while positivity for CD34 is extremely rare 35,103.

SS is characterised by a translocation involving chromosomes X and 18. This translocation is reported only in SS, and results in three alternative fusion products of the SS18 gene with either SSX1, or SSX2 or SSX4 gene 99. FISH analysis and amplification of the specific chimeric transcript by RT-PCR are effective techniques to detect translocation t (18; X), representing ancillary tools for diagnosis of SS 99,104. Very recently a novel SS18-SSX fusion-specific antibody has been developed (Fig. 36D) showing a highly sensitivity and specificity for SS. This specific antibody may replace molecular genetic testing for diagnostic confirmation of SS. The main differential diagnosis of monophasic SS is with GIST. Histological features and positivity for CD117 and DOG1 stainings are usually sufficient to support the diagnosis GIST 15. Importantly, focal positivity for DOG1 has been reported in SS of the digestive system, representing a possible diagnostic pitfall 105. Moreover, cytokeratin positivity has been observed in sporadic GISTs 106,107. S100 positive monophasic SS may enter in differential diagnosis with gastrointestinal clear cell sarcomas (CCS) and CCS-like tumours of the GI tract 68. Negativity for epithelial markers and EWSR1 gene rearrangements are distinctive features of CCS and CCS-like tumours 68,98,108. Markers of melanocytic differentiation (e.g. MelanA/MART1, HMB45 and MiTF) are commonly expressed in CCS (but not in CCS-like tumors), helping in the differential diagnosis with SS 68. Monophasic SSs may also enter in diagnosis with leiomyosarcomas, malignant spindle cell melanomas and spindle cell squamous cell carcinoma. However, a higher degree of pleomorphism is usually observed in all these lesions. Expression of smooth muscle markers and melanocytic markers can easily direct the diagnosis toward leiomyosarcoma and melanoma, respectively. Spindle cell squamous cell carcinoma is usually characterised by a stronger expression of epithelial markers and by the presence of areas of conventional carcinoma 99. Despite the fact that morphological and immunohistochemical features most often make the diagnosis of biphasic SS relatively easy, the differential diagnosis with gastroblastoma may sometimes be considered. Gastroblastoma is an extremely rare mixed epithelial-mesenchymal neoplasm with just a few cases reported in the literature 109,110. The mesenchymal component consists of spindle cells with minimal to mild nuclear atypia and variable mitotic activity, while the epithelial one is composed by epithelioid cells organised in sheets, nests, or cords with no or mild nuclear atypia 109,110. Immunohistochemistry is helpful in the assessment of the correct diagnosis, since gastroblastomas are negative for SSX-SYT, EMA and TLE1; moreover, gastroblastoma lacks SYT gene rearrangements.

Conclusions

Mesenchymal tumours represent an extremely heterogeneous group of lesions. Visceral locations are increasingly recognised due to refinement of diagnostic criteria. Even if GIST represent by far the commonest lesion (at least in the stomach), actually mesenchymal neoplasms may occur in the GI-tract. Accurate diagno-
sis can be challenging, but represents the cornerstone of accurate therapeutic planning. The combination of morphologic, immunophenotypic and molecular findings represents the best strategy to allow accurate classification.

References

1. Sbaraglia M, Dei Tos AP. The pathology of soft tissue sarcomas. Radiol Med 2019;124:266-281. https://doi.org/10.1007/s11547-018-0882-7
2. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica 2021;113:70-84. https://doi.org/10.32074/1591-951X-213. Epub 2020 Nov 3. PMID: 33179614
3. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer 2019
4. Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010;34:1480-1491. https://doi.org/10.1097/PAS.0b013e3181f7431
5. Miettinen M, El-Rifai W, Sobin LHL, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-483. https://doi.org/10.1053/hupa.2002.124123
6. Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011;35:1646-1656. https://doi.org/10.1097/PAS.0b013e3182243647
7. Joensuu H, Vehlari A, Rihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265-274. https://doi.org/10.1016/S1470-2045(11)70299-6
8. Casali PG, Abeecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv267. https://doi.org/10.1093/annonc/mdy095
9. Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 2018;72:106-116. https://doi.org/10.1111/his.13277
10. Gasparotto D, Rossi S, Polano M, et al. Quadruple-negative GIST is a sentinel for unrecognized neurofibromatosis type 1 syndrome. Clin Cancer Res 2017;23:273-282. https://doi.org/10.1158/1078-0432.CCR-16-0152
11. Agaimy A, Otto C, Braun A, et al. Value of epithelioid morphology and PDGFRA immunostaining pattern for prediction of PDGFRA mutated genotype in gastrointestinal stromal tumors (GISTs). Int J Clin Exp Pathol 2013;6:1839-1846
12. Antonescu CR, Romeo S, Zhang L, et al. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol 2013;37:385-392. https://doi.org/10.1097/PAS.0b013e31826c1761
13. Ibrahim A, Chopra S. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med 2020;144:655-660. https://doi.org/10.1093/arp/aar.2018-0370-RS
14. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008;32:210-218. https://doi.org/10.1097/PAS.0b013e318221238ec
15. Novelli M, Rossi S, Rodriguez-Justo M, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57:259-270. https://doi.org/10.1111/j.1365-2559.2010.03624.x
16. Wagner AJ, Remillard SP, Zhang YX, et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013;26:289-294. https://doi.org/10.1038/modpathol.2012.153
17. Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol 2015;39:922-930. https://doi.org/10.1097/PAS.0000000000000418
18. Wada R, Arai H, Kure S, et al. “Wild type” GIST: clinicopathological features and clinical practice. Pathol Int 2016;66:431-437. https://doi.org/10.1111/pin.12431
19. Yamamoto H, Toto B, Nakamori M, et al. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol 2009;135:791-798. https://doi.org/10.1007/s00432-008-0514-z
20. Brench M, Rossi S, Polano M, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 2016;238:543-549. https://doi.org/10.1002/path.4677
21. Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 2020;31:1506-1517. https://doi.org/10.1016/j.annonc.2020.08.2232
22. Chung J, Namkoong S, Jung KE, et al. A Case of Gardner’s Syndrome Associated with Desmoid Tumor. Ann Dermatol 2010;22:418-221. https://doi.org/10.5021/ad.2010.22.4.418
23. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-1527. https://doi.org/10.2353/ajpath.2008.080475
24. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96-107. https://doi.org/10.1016/j.ejca.2019.11.013. Epub 2020 Jan 28. PMID: 32004793
25. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007;31:509-520. https://doi.org/10.1097/01.pas.0000213393.57322.c7
26. Marinho-Enriquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 2011;35:135-144. https://doi.org/10.1097/PAS.0b013e318200c0d5
27. LI J, Yin WH, Takeuchi K, et al. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review. Diagn Pathol 2013;8:147. https://doi.org/10.1186/1746-1596-8-147
28. Lee JC, Li CF, Huang HY, et al. ALK oncogenes in atypical inflammatory myofibroblastic tumors: novel RRB1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 2017;241:316-323. https://doi.org/10.1002/path.4836
29. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myo-
fibroblastic tumor. Am J Pathol 2001;159:411-415. https://doi.
.org/10.1016/S0002-9440(10)61711-7

Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular charac-
terization of inflammatory myofibroblastic tumors with frequent
ALK and ROS1 gene fusions and rare novel RET rearrange-
ment. Am J Surg Pathol 2015;39:957-967. https://doi.org/10.1097/
PAS.0000000000000404

Alasii AH, Ali RH, Shen Y, et al. ETV6-NTRK3 is expressed in a
subset of ALK-negative inflammatory myofibroblastic tumors.
Am J Surg Oncol 2016;40:1051-1061. https://doi.org/10.1097/
PAS.0000000000000677

WHO Classification of Tumours Editorial Board. Soft tissue and
bone tumours. 5th ed. Lyon (France): IARC 2020.

Gholami S, Cassidy MR, Kirane A, et al. Size and Location are
the Most Important Risk Factors for Malignant Behavior in Re-
sected Solitary Fibrous Tumors. Ann Surg Oncol 2017;24:3865-
3871. https://doi.org/10.1245/s10434-017-6092-z

Pasquali S, Gronchi A, Strauss D, et al. Resectable extra-pleural
and extra-meninginal solitary fibrous tumours: A multi-centre
prognostic study. Eur J Surg Oncol 2016;42:1064-1070. https://
doi.org/10.1016/j.ejso.2016.01.023

Businello G, Dal Pozzo CA, Sbaraglia M, et al. Histopathologi-
cal landscape of rare oesophageal neoplasms. World J Gas-
troenterol 2020;26:3865-3888. https://doi.org/10.3748/wjg.v26.
i27.3865

Inayat F, Hussain Q, Shafique K, et al. Solitary Fibrous Tu-
mor of the Stomach. ACG Case Rep J 2017;4:e35. https://doi.
.org/10.14309/crj.2017.35

Dey B, Gothait D, Kaushal G, et al. Solitary Fibrous Tumor of the
Liver: A Rare Tumor in a Rarer Location. Rare Tumors 2016;8:6403-
6403. https://doi.org/10.4081/path.2016.16403

D’Amico FE, Ruffolo C, Romano M, et al. Rare neoplasm mim-
icking neuroendocrine pancreatic tumor: a case report of soli-
dary fibrous tumor with review of the literature. Anticancer Res
2017;37:3093-3097. https://doi.org/10.21873/anticancer.11665

Folpe AL, Devaney K, Weiss SW. Lipomatous hemangiopericy-
toma: a rare variant of hemangiopericytoma that may be con-
fused with liposarcoma. Am J Surg Pathol 1999;23:1201-1207.
https://doi.org/10.1097/00000478-199910000-00004

Guillou L, Gebhard S, Coinerde JM. Orbital and extraorbital giant
cell angiofibroma: a giant cell-rich variant of solitary fibrous tumor:
Clinicopathological and immunohistochemical analysis of a series
in favor of a unifying concept. Am J Surg Pathol 2000;24:971-
979. https://doi.org/10.1097/00000478-200007000-00008

Olson NJ, Linos K. Dedifferentiated Solitary fibrous tumor: a con-
cise review. Arch Pathol Lab Med 2018;142:761-766. https://doi.
.org/10.5858/arpa.2016-0570-RS

Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression
of p16INK4A in angiofibromas: a giant cell-rich variant of solitary fibrous tu-
mor of the stomach. A special reference to an immunohistochemical
study. Am J Surg Pathol 2015;39:957-967. https://doi.org/10.1097/
PAS.0000000000000677

Caliskan A, Kohliman WK, Aftoler KE, et al. Intramucosal li-
pomas of the colon implicate Cowden syndrome. Mod Pathol
2018;31:643-651. https://doi.org/10.1038/modpathol.2017.161

Spans L, Fletcher CD, Antonescu CR, et al. Recurrent MALAT1-
GL1 oncogenic fusion and GL11 up-regulation define a subset of
plexiform fibromyxoma. J Pathol 2016;239:335-343. https://doi.
.org/10.1002/path.4730

Caliskan A, Kohliman WK, Aftoler KE, et al. Intramucosal li-
pomas of the colon implicate Cowden syndrome. Mod Pathol
2018;31:643-651. https://doi.org/10.1038/modpathol.2017.161

Farfou AN, AbuOmar NA, Alshoaiabani F. Large lipoma of the
ascending colon: a case report and review of literature. J Surg
Case Rep 2020;2020(9):rja3354. https://doi.org/10.1038/jscr.
rja3354

Sun J, Kang W, Zeng Z, et al. Rare localization of angio-
fibroma in the gastrointestinal tract: a case series. J Int
Med Res 2020;48(3):300060520938589. https://doi.
.org/10.1177/0022215192038589

Bartum H, Panagopoulos I, Collin A, et al. Expression levels of
HMGA2 in adipocytic tumors correlate with morphologic
and cytogenetic subgroups. Mol Cancer 2009;8:36. https://doi.org/10.1186/1476-4598-8-36

62 Enzinger FM, Weiss SW. Liposarcoma. St Louis: Mosby 1995, pp. 431-466

Gajzer DC, Fletcher CD, Agaimy A, et al. Primary gastrointestinal liposarcoma—a clinicopathological study of 8 cases of a rare entity. Hum Pathol 2020;97:80-93. https://doi.org/10.1016/j.humpath.2019.12.004

De Vita A, Mercatali L, Recine F, et al. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther 2016;9:6233-46. https://doi.org/10.2147/OT.2112580

Ben Safta Y, Souai F, Maatouk M, et al. Myxoid esophageal liposarcoma: A case report of a rare tumor. Int J Surg Case Rep 2019;60:69-71. https://doi.org/10.1016/j.ijscr.2019.04.001

Sonoda A, Sawayama H, Miyani N, et al. Giant myxoid liposarcoma of the stomach: Report of a case. Int J Surg Case Rep 2019;60:234-8. https://doi.org/10.1016/j.ijscr.2019.06.025

Miettinen M, Enzinger FM. Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol 1999;12:722-728.

Doyle LA, Horlick JL. Mesenchymal Tumors of the Gastrointestinal Tract Other than GiST. Surg Pathol Clin 2013;6:425-473. https://doi.org/10.1016/j.path.2013.05.003

Takubo K, Nakagawa H, Tsuchiya S, et al. Seeding leiomyoma of the esophagus and esophagogastric junction zone. Hum Pathol 1981;12(11):1006-10. https://doi.org/10.1016/s0046-8177(81)80257-2

Yamamoto H, Handa M, Tobo T, et al. Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours. Histopathology 2013;63(2):194-207. https://doi.org/10.1111/his.12159

Hilal L, Barada K, Mukherji D, et al. Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis. Med Oncol 2016;33:20. https://doi.org/10.1007/s12032-016-0730-3

McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 1995;332:12-18. https://doi.org/10.1056/NEJM1995053320103

Miettinen M, Sobin LH, Lasota J. True smooth muscle tumors and leiomyosarcomas in the colon and rectum: a clinicopathologic, immunohistochemical, and molecular genetic study of 25 cases. Am J Surg Pathol 2009;33:430-436. https://doi.org/10.1097/PAS.0b013e3181877f2

Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001;25:1121-1133. https://doi.org/10.1097/01.PAS.00000478-20009000-00002

Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000;24:1339-1352. https://doi.org/10.1097/00000478-20001000-00003

Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000;24:211-222. https://doi.org/10.1097/00000478-20002000-00007

Deyrup AT, Lee VK, Hill CE, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 2006;30:75-82. https://doi.org/10.1097/01.pas.0000178088.69394.7b

Guo X, Jo VY, Mills, et al. Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clin Cancer Res 2015;21:3501-3511. https://doi.org/10.1158/1078-0432.CCR-14-3141

Italiano A, Lagarde P, Brulard C, et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. Clin Cancer Res 2013;19:1190-1196. https://doi.org/10.1158/1078-0432.CCR-12-2970

Gibson JA, Hornick JL. Mucosal Schwann cell “hamarto:ma”: clinicopathologic study of 26 neural colorectal polyps distinct from neurofibromas and mucosal neuromas. Am J Surg Pathol 2009;33:781-787. https://doi.org/10.1097/PAS.0b013e318186d6ca

Pasquini P, Baiocchini A, Falasca, et al. Mucosal Schwann cell “Hamartoma”: a new entity? World J Gastroenterol 2009;15:2287-2289. https://doi.org/10.3748/wjg12876-015-0349-4

Miettinen M, Shekitka KM, Sobin LH. Schwannomas in the colon and rectum: a clinicopathologic and immunohistochemical study of 20 cases. Am J Surg Pathol 2001;25:846-855. https://doi.org/10.1097/00000478-200107000-00002

Levy AD, Quiles AM, Miettinen M, et al. Gastrointestinal schwannomas: CT features with clinicopathologic correlation. AJR Am Roentgenol 2005;184:797-802. https://doi.org/10.2214/ajr.184.3.01840797

Sarlo-Rikala M, Miettinen M. Gastric schwannoma—a clinicopathological analysis of six cases. Histopathology 1995;27:355-360. https://doi.org/10.1111/j.1365-2559.1995.tb01526.x

Volkaggio L, Murray R, Lasota J, et al. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature. Hum Pathol 2012;43:650-659. https://doi.org/10.1016/j.humpath.2011.07.006

Lieg B, Bennett MW, Fletcher CD. Microcystic/reticular schwannoma: a distinct variant with predilection for visceral locations. Am J Surg Pathol 2008;32:1080-1087. https://doi.org/10.1097/PAS.0b013e318160cfda

Hou YF, Tan YS, Xu JF, et al. Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology 2006;48:536-545. https://doi.org/10.1111/j.1365-2559.2006.02370.x

Lasota J, Wasag B, Dansonka-Mieszkowska A, et al. Evaluation of NF2 and NF1 tumor suppressor genes in distinctive gastrointestinal nerve sheath tumors traditionally diagnosed as benign schwannomas: a study of 20 cases. Lab Invest. 2003;83:1361-1371. https://doi.org/10.1038/10780

Miettinen M, Maal E, Lasota J, et al. Gastrointestinal glomus tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol 2002;26:301-311. https://doi.org/10.1097/01.PAS.00000478-20020300-00003

Kihara A, Fukushima J, Horuchi H, Glomus tumor of the liver presenting as a cystic lesion. Pathol Int 2014;64:295-297. https://doi.org/10.1111/pin.12169

Kihara K, Matsui T, Nagano H, et al. Atypical glomus tumor arising in the liver: a case report. Diagn Pathol 2010;5:10.1186/1746-1596-5-10. https://doi.org/10.1186/1746-1596-5-10

Mosquera JM, Sboner A, Zhang L, et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chro- mosomes Cancer 2013;52:1075-1087. https://doi.org/10.1002/gcc.22102
93. Karamzadeh Dashti N, Bahrami A, Lee SJ, et al. BRAF V600E mutations occur in a subset of glomus tumors, and are associated with malignant histologic characteristics. Am J Surg Pathol 2017;41:1532-1541. https://doi.org/10.1097/PAS.0000000000000913

94. Pulitzer DR, Martin PC, Reed RJ. Epithelioid glomus tumor. Hum Pathol 1995;26:1022-1027. https://doi.org/10.1016/0046-8177(95)90093-4

95. Slater DN, Cotton DW, Azzopardi JG. Oncocytic glomus tumour: a new variant. Histopathology 1987;11:523-531. https://doi.org/10.1111/j.1365-2559.1987.tb02660.x

96. Folpe AL, Fanburg-Smith JC, Miettinen M, et al. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol 2001;25:1-12. https://doi.org/10.1097/00000478-200101000-00001

97. Sbaraglia M, Zanatta L, Toffolatti L, et al. Clear cell sarcoma-like/malignant gastrointestinal neuroectodermal tumor of the tongue: a clinicopathologic and molecular case report. Virchows Arch 2021;478:1203-1207. https://doi.org/10.1007/s00428-020-02932-2. Epub 2020 Oct 2. PMID: 33005982

98. Stockman DL, Miettinen M, Suster S, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol 2012;36:857-868. https://doi.org/10.1097/PAS.0b013e31824644ac

99. Romeo S, Rossi S, Acosta Marín M, et al. Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases. Clin Sarcoma Res 2015;5:7. https://doi.org/10.1186/s13569-015-0021-3

100. Doroudinia A, Bakhshayesh Karam M, Doroudinia A, et al. Synovial sarcoma of the esophagus: a case report and review of literature. Middle East J Dig Dis 2017;9:111-113. https://doi.org/10.15171/mejdj.2017.60

101. Majeste RM, Beckman EN. Synovial sarcoma with an overwhelming epithelial component. Cancer. 1988;61:2527-2531. https://doi.org/10.1002/1097-0142(19880615)61:12<2527::aid-cncr2820611223>3.0.co;2-6

102. Folpe AL, Schmidt RA, Chapman D, et al. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998;22:673-682. https://doi.org/10.1097/00000478-199806000-00004

103. Fisher C, Schofield JB. S-100 protein positive synovial sarcoma. Histopathology 1991;19:375-377. https://doi.org/10.1111/j.1365-2559.1991.tb00555.x

104. Coindre JM, Pelzus M, Hostein I, et al. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98:2700-2707. https://doi.org/10.1002/cncr.11840

105. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33:1401-1408. https://doi.org/10.1097/PAS.0b013e3181a90e1a

106. Rossi G, Sartori G, Valli R, et al. The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J Clin Pathol 2005;58:991-993. https://doi.org/10.1136/jcp.2004.024364

107. Lippai N, Füle T, Németh T, et al. Keratin-positive gastrointestinal stromal tumor of the stomach mimicking gastric carcinoma: diagnosis confirmed by c-kit mutation analysis. Diagn Mol Pathol 2008;17:241-244. https://doi.org/10.1097/PDM.0b013e31816184c6

108. D’Amico FE, Ruffolo C, Romeo S, et al. Clear cell sarcoma of the ileum: report of a case and review of the literature. Int J Surg Pathol 2012;20:401-406. https://doi.org/10.1177/1066896911428073

109. Toumi O, Ammar H, Korbi I, et al. Gastroblastoma, a biphasic neoplasm of stomach: a case report. Int J Surg Case Rep 2017;39:72-6. https://doi.org/10.1016/j.ijscr.2017.06.061

110. Wey EA, Britton AJ, Sferra JJ, et al. Gastroblastoma in a 28-year-old man with nodal metastasis: proof of the malignant potential. Arch Pathol Lab Med 2012;136:961-964. https://doi.org/10.5858/arpa.2011-0372-CR